pipeline

CANCER THERAPEUTICS PIPELINE:

MicrolinBio Pipeline


LUMIRALIN™

miR-21 based therapeutics for lung cancer in discovery and optimization phase.

> Results showed that miR-21 is commonly upregulated in NSCLC cell lines and tissues with important functional consequences

> anti-miR-21 significantly inhibits growth, migration and invasion, and reverse chemo- or radioresistance of NSCLC cells


OMIRALIN™

miR-484 based therapeutics for ovarian cancer in discovery and optimization phase

> miR-484 revealed that the sensitive phenotype is caused by a modulation of tumor vasculature through the regulation of the VEGFB and VEGFR2 pathways

> multicenter cohort demonstrated that mir 484 was involved in the control of ovarian tumor angiogenesis


COLOMIRALIN™

miR-17 cluster (6 miRs) based therapeutics for colon cancer in discovery phase.

> miR-17-5p inhibitor showed growth inhibition, spontaneous apoptosis, higher caspase-3 activation, and increased chemosensitivity to gemcitabine

> Among one of the most recognized in multiple types of cancers


PROMIRALIN™

undisclosed miR-based therapeutics for prostate cancer in early discovery phase.

> Identifying potential targets in collaboration with Carlo Croce’s Lab